Added to YB: 2025-02-10
Pitch date: 2024-12-24
KNSA [bullish]
Kiniksa Pharmaceuticals International, plc
+139.44%
current return
Author Info
No bio for this author
Company Info
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
Market Cap
$3.4B
Pitch Price
$19.70
Price Target
40.00 (-15%)
Dividend
N/A
EV/EBITDA
69.82
P/E
97.19
EV/Sales
5.18
Sector
Biotechnology
Category
growth
Kiniksa Pharmaceuticals International, plc - $KNSA
KNSA: ARCALYST for RP at 11% penetration, $450M run-rate rev, 68% YoY Q3 growth. $1.2B 2030 sales target. Pipeline: abiprubart (Sjögren's), mavrilimumab (GCA), vixarelimab (prurigo nodularis). $40 PT (100% upside), 2.8x RR rev vs 5-7x peers. Risks: execution, competition. Catalysts: earnings, clinical data.
Read full article (4 min)